Table 2 ASM use of 3 patients (4 pregnancies) with unexpected fetal losses before and during pregnancy
From: Hippocampal sclerosis in women with temporal lobe epilepsy: seizure and pregnancy outcomes
| Â | Fetal outcomes | ASM use before pregnancy | Time | ASM change during pregnancy | Seizure frequency before pregnancy | Frequency change during pregnancy | Folic acid intake |
|---|---|---|---|---|---|---|---|
Patient 1 | fetal death | LEV 0.5g bid | Week 13 | stopped and resumed later | FIAS: yearly; FBTCS: yearly | increase (six times per month) | 800μg/day qd for the first three months of pregnancy |
Patient 2 | spontaneous abortion | VPA 0.4g bid; CBZ 0.2g bid | Week 4 | no change | FIAS: daily | no change | no |
Patient 2 | spontaneous abortion | VPA 0.4g bid; CBZ 0.2g bid; TPM 50mg bid; | Week 8 | no change | seizure-free for three years after surgery | no change | no |
Patient 3 | spontaneous abortion | LTG 50mg bid; LEV 0.5g bid | Week 6 | stopped and resumed later | FIAS: monthly; FBTCS: seizure free for more than a year | no change | 400μg/day qd for the first three months before pregnancy |